Table 1.
Patient Background Data (n=11)
| Backgrounds | Median [Interquartile Range] or Number (%) |
|---|---|
| Age, years | 64.6 [60.0–75.1] |
| Sex, Male/Female | 2 (18.2)/9 (81.8) |
| Time from diagnosis until the initiation of treatment, years | 13.7 [6.3–15.8] |
| Weight, kg | 49.4 [44.7–51.5] |
| BMI, kg/m2 | 19.8 [16.4–22.4] |
| Smoking history | 2 (18.2) |
| Medical history | |
| Bronchial asthma | 2 (18.2) |
| Malignancy | 2 (18.2) |
| Diabetes mellitus | 1 (9.1) |
| Mycobacterium species | |
| M. avium | 10 (90.9) |
| M. intracellulare | 1 (9.1) |
| Presence of cavitary lung lesions | 4 (36.4) |
| Radiological pattern | |
| NB/FC/NB+FC/unclassified | 8 (72.7)/0 (0)/3 (27.3)/0 (0) |
| Number of GBT drugs in regimen (at baseline) | |
| 0/1/2/3/4 or more | 0 (0)/0 (0)/5 (45.5)/4 (36.4)/2 (18.2) |
| Drug class (at baseline) | |
| Macrolide | 9 (81.8) |
| Ethambutol | 10 (90.9) |
| Rifamycin | 8 (72.7) |
| Fluoroquinolone | 3 (27.3) |
| Others | 0 (0) |
| Generic name of drug (at baseline) | |
| Clarithromycin | 3 (27.3) |
| Azithromycin | 3 (27.3) |
| Erythromycin | 3 (27.3) |
| Ethambutol | 10 (90.9) |
| Rifampicin | 8 (72.7) |
| Sitafloxacin | 3 (27.3) |
Abbreviations: FC, fibrocavitary type; GBT, guideline-based therapy; NB, nodular bronchiectatic type.